IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v86y2008i1p85-96.html
   My bibliography  Save this article

An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy

Author

Listed:
  • Kontodimopoulos, Nick
  • Niakas, Dimitris

Abstract

Objectives To estimate lifelong costs and quality adjusted life years (QALYs) of hemodialysis (HD), peritoneal dialysis (PD) and renal transplantation (Tx) in Greece, based on individual patient life expectancy.Methods A nationally representative patient sample on each modality, HD: NÂ =Â 642, PD: NÂ =Â 65 and Tx: NÂ =Â 167, was self-administered the SF-36 Health Survey, from which the preference-based SF-6D utility index was derived. Lifelong QALYs were estimated from literature-based expected remaining life years according to age, gender and modality. Cost analyses were performed from the perspective of the health system. Costs and QALYs were discounted at 5% and sensitivity analyses were performed.Results Estimated lifelong QALYs were 4.37 (HD), 3.94 (PD) and 16.11 (Tx) (PÂ

Suggested Citation

  • Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    • Handle: RePEc:eee:hepoli:v:86:y:2008:i:1:p:85-96
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(07)00230-8
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Wolfgang C. Winkelmayer & Milton C. Weinstein & Murray A. Mittleman & Robert J. Glynn & Joseph S. Pliskin, 2002. "Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment," Medical Decision Making, , vol. 22(5), pages 417-430, October.
    2. Brazier, John & Roberts, Jennifer & Deverill, Mark, 2002. "The estimation of a preference-based measure of health from the SF-36," Journal of Health Economics, Elsevier, vol. 21(2), pages 271-292, March.
    3. Stirling Bryan & Louise Longworth, 2005. "Measuring health-related utility:," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 253-260, September.
    4. Ruth Etzioni & Scott D. Ramsey & Kristin Berry & Martin Brown, 2001. "The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study," Health Economics, John Wiley & Sons, Ltd., vol. 10(3), pages 245-256, April.
    5. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
    6. Louise Longworth & Stirling Bryan, 2003. "An empirical comparison of EQ‐5D and SF‐6D in liver transplant patients," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1061-1067, December.
    7. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    8. Bernie J. O'Brien & Marian Spath & Gordon Blackhouse & J.L. Severens & Paul Dorian & John Brazier, 2003. "A view from the bridge: agreement between the SF‐6D utility algorithm and the Health Utilities Index," Health Economics, John Wiley & Sons, Ltd., vol. 12(11), pages 975-981, November.
    9. John M. Miyamoto & Stephen A. Eraker, 1985. "Parameter Estimates for a QALY Utility Model," Medical Decision Making, , vol. 5(2), pages 191-213, June.
    10. Peeters, Pascale & Rublee, Dale & Just, Paul M. & Joseph, Alain, 2000. "Analysis and interpretation of cost data in dialysis: review of Western European literature," Health Policy, Elsevier, vol. 54(3), pages 209-227, December.
    11. Ben A. Van Hout, 1998. "Discounting costs and effects: a reconsideration," Health Economics, John Wiley & Sons, Ltd., vol. 7(7), pages 581-594, November.
    12. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Trevor A. Ellison & Samantha Clark & Jonathan C. Hong & Kevin D. Frick & Dorry L. Segev, 2021. "Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 403-414, May.
    2. Ellen Busink & Dana Kendzia & Fatih Kircelli & Sophie Boeger & Jovana Petrovic & Helen Smethurst & Stephen Mitchell & Christian Apel, 2023. "A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 377-392, April.
    3. Fei Yang & Meixia Liao & Pusheng Wang & Zheng Yang & Yongguang Liu, 2021. "The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations," Applied Health Economics and Health Policy, Springer, vol. 19(2), pages 163-180, March.
    4. Joseph Menzin & Lisa Lines & Daniel Weiner & Peter Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne, 2011. "A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease," PharmacoEconomics, Springer, vol. 29(10), pages 839-861, October.
    5. Bernadette Li & John Cairns & James Fotheringham & Rommel Ravanan, 2016. "Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(6), pages 659-668, July.
    6. Martin Howell & Rachael C. Walker & Kirsten Howard, 2019. "Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations," Applied Health Economics and Health Policy, Springer, vol. 17(3), pages 315-330, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Garry R. Barton & Tracey H. Sach & Anthony J. Avery & Claire Jenkinson & Michael Doherty & David K. Whynes & Kenneth R. Muir, 2008. "A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 815-832, July.
    2. Carmen Selva-Sevilla & Paula Ferrara & Manuel Gerónimo-Pardo, 2020. "Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 649-662, June.
    3. Silvia Garrido & Ildefonso Méndez & José-María Abellán, 2013. "Analysing the Simultaneous Relationship Between Life Satisfaction and Health-Related Quality of Life," Journal of Happiness Studies, Springer, vol. 14(6), pages 1813-1838, December.
    4. Nick Kontodimopoulos & Evelina Pappa & Zinovia Chadjiapostolou & Eleni Arvanitaki & Angelos Papadopoulos & Dimitris Niakas, 2012. "Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 111-120, February.
    5. Nick Kontodimopoulos & Michalis Argiriou & Nikolaos Theakos & Dimitris Niakas, 2011. "The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(4), pages 383-391, August.
    6. Cecilia Quercioli & Gabriele Messina & Emanuela Barbini & Giovanni Carriero & Mara Fanì & Nicola Nante, 2009. "Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(4), pages 389-397, October.
    7. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
    8. Bruno Casal & Eva Rodríguez-Míguez & Berta Rivera, 2020. "Measuring intangible cost-of-morbidity due to substance dependence: implications of using alternative preference-based instruments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 1039-1048, September.
    9. Richard Grieve & Marina Grishchenko & John Cairns, 2009. "SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 15-23, February.
    10. Richard Huan Xu & Dong Dong & Nan Luo & Eliza Lai-Yi Wong & Yushan Wu & Siyue Yu & Renchi Yang & Junshuai Liu & Huiqin Yuan & Shuyang Zhang, 2021. "Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 547-557, June.
    11. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    12. Janelle Seymour & Paul McNamee & Anthony Scott & Michela Tinelli, 2010. "Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ‐5D and SF‐6D responses," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 683-696, June.
    13. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    14. Fan Yang & Titus Lau & Evan Lee & A. Vathsala & Kee Chia & Nan Luo, 2015. "Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD)," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 1019-1026, December.
    15. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    16. Roisin Adams & Cathal Walsh & Douglas Veale & Barry Bresnihan & Oliver FitzGerald & Michael Barry, 2010. "Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis," PharmacoEconomics, Springer, vol. 28(6), pages 477-487, June.
    17. Marra, Carlo A. & Woolcott, John C. & Kopec, Jacek A. & Shojania, Kamran & Offer, Robert & Brazier, John E. & Esdaile, John M. & Anis, Aslam H., 2005. "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis," Social Science & Medicine, Elsevier, vol. 60(7), pages 1571-1582, April.
    18. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    19. Rutten, Frans & Bleichrodt, Han & Brouwer, Werner & Koopmanschap, Marc & Schut, Erik, 2001. "Handbook of Health Economics," Journal of Health Economics, Elsevier, vol. 20(5), pages 855-879, September.
    20. Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton, 2018. "Discounting in Economic Evaluations," PharmacoEconomics, Springer, vol. 36(7), pages 745-758, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:86:y:2008:i:1:p:85-96. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.